Breast Lift in AL
Breast Lift in AL section, includes general infrmation about Breast Lift Procedure, Breast Lift AL Local News, Breast Lift AL Surgeon Locator and other Breast Lift related material.
Breast Lift Procedure
A mastopexy or breast lift is a surgical procedure performed to reshape the breast and return it to a more youthful position. Drooping of the breast may occur after pregnancy as well as aging. Frequently a breast implant may be used in conjunction with a breast lift in order to achieve better results. Depending on the amount of breast lifting that needs to be accomplished, different techniques may be used that involve different incisions. Generally, the more lifting that is required, the larger the incision (and therefore the scar).
Other Breast Lift Procedures
All Breast Procedures
Breast Lift AL (current)
AL Breast Reduction
AL Breast Implants
AL Implant Removal
AL Armpit Incision
More AL info...
Plastic Surgery News...
- A study by researchers in South Korea found that snoring influenced the development of chronic bronchitis, but how and why remained somewhat of a mystery.The research was carried out by scientists at Korea University Ansan Hospital, in Ansan, South Korea, and is published in the 28th January issue of the Archives of Internal Medicine.
- According to PharmaLive, the FDA has approved abatacept (Orencia®) for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in paediatric patients aged six years and above. It may be used as monotherapy or concomitantly with methotrexate (MTX), but should not be used concomitantly with tumour necrosis factor (TNF) antagonists or other biological therapy (e.g. anakinra).
This approval is based on the AWAKEN trial, which included 190 patients aged 6-17 years with moderately to severely active polyarticular JIA who had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). The first part was a 4-month, open-label lead-in phase in which patients received IV abatacept (10 mg/kg; maximum 1,000 mg) on Days 1, 15, 29 and every month thereafter. Those who achieved an ACR Pedi 30 response entered Period B - a six-month, double-blind phase involving randomisation to remain on abatacept (n=60) or to receive placebo (n=62) for six months. The primary endpoint of the study was time to occurrence of disease flare.
The main findings were as follows:
• In the lead-in phase, abatacept treatment resulted in a consistent improvement in ACR Pedi 30 across all JIA subtypes (oligoarticular extended - 59.3%; polyarticular-RF positive - 68.4%; polyarticular-RF negative - 64.3%; and systemic JIA with polyarticular course - 64.9%)
• The time to occurrence of disease flare was statistically significantly longer in patients treated with abatacept compared to patients treated with placebo compared with abatacept (p=0.0002) [no specific details given on magnitude of this difference]
• Patients treated with abatacept experienced fewer disease flares compared to placebo-treated patients (20% versus 53%, respectively, p<0.001)
• The risk of disease flare among patients continuing on abatacept was less than that for patients who withdrew from abatacept treatment (HR 0.31, 95% CI 0.16 to 0.59)
Please see the link above for further details.